Frank Herting

USPTO Granted Patents = 13 (Patent Applications = 33)

CIPO Patents = 4 (Patent Applications = 5)

EPO Patents = 9 (Patent Applications = 14)

Average Co-Inventor Count = 6.1

ph-index = 3

Forward Citations = 72(Granted Patents)

Location History:

Sindelsdorf, DE (2008 - 2009)
Penzberg, DE (2006 - 2022)

Company Filing History:

11 out of 4,945

Hoffmann-la Roche Inc.

Years Active: 2006-2022

Loading Chart...

13 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11525007 - Antibody fab and Fc variants (2022-12-13),

2. 11512133 - Methods for treating colon cancer or inhibiting cell proliferation by administering a combination of antibodies against human CSF-1R and antibodies against human PD-L1 (2022-11-29),

3. 10683345 - Bispecific anti-VEGF/anti-ANG-2 antibodies and their use in the treatment of ocular vascular diseases (2020-06-16),

4. 9695233 - Bispecific anti-VEGF/anti-ANG-2 antibodies and their use in the treatment of ocular vascular diseases (2017-07-04),

5. 7638553 - Hydroxamates, their manufacture and use as pharmaceutical agents (2009-12-29),

6. 7501451 - Mono-acylated o-phenylendiamines derivatives (2009-03-10),

7. 7423060 - Thiophene hydroxamic acid derivatives and their use as HDAC inhibitors (2008-09-09),

8. 7396944 - Thiophene derivatives, their manufacture and use as pharmaceutical agents (2008-07-08),

9. 7208491 - N-monoacylated o-phenylenediamines (2007-04-24),

10. 7173060 - Oxime derivatives and their use as pharmaceutically active agents (2007-02-06),

11. 7098247 - Arylene-carboxylic acid (2-amino-phenyl)-amide derivatives (2006-08-29),

12. 7098241 - Thiophene hydroxamic acid derivatives (2006-08-29),

13. 7071219 - Mono-acylated o-phenylendiamines derivatives (2006-07-04),

Title: Frank Herting: Innovator in Antibody Technology

Introduction

Frank Herting is a notable inventor based in Penzberg, Germany. He has made significant contributions to the field of biotechnology, particularly in the development of modified antibodies. With a total of 13 patents to his name, Herting's work has advanced the understanding and application of antibody therapies.

Latest Patents

Herting's latest patents include innovations related to antibody fab and Fc variants. These inventions focus on modified antibodies, specifically recombinant monoclonal antibodies that possess altered abilities to induce direct cell death and enhance effector function. Additionally, his patents cover nucleic acid molecules encoding such antibodies, as well as vectors and host cells that incorporate these nucleic acids. His work also includes methods for producing these antibodies and their application in treating diseases. Notably, he has developed methods for treating colon cancer by administering a combination of antibodies against human CSF-1R and PD-L1.

Career Highlights

Throughout his career, Frank Herting has worked with prominent companies in the biotechnology sector. He has been associated with Hoffmann-La Roche Inc. and Roche Glycart AG, where he has contributed to various innovative projects. His expertise in antibody technology has positioned him as a key figure in the industry.

Collaborations

Herting has collaborated with several professionals in his field, including Anja Limberg and Georg Fertig. These partnerships have facilitated the advancement of his research and the successful development of his patented technologies.

Conclusion

Frank Herting's contributions to antibody technology have had a profound impact on the field of biotechnology. His innovative patents and collaborations reflect his commitment to advancing medical treatments through scientific research. His work continues to influence the development of effective therapies for various diseases.

This text is generated by artificial intelligence and may not be accurate.